Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc, discusses how much anticancer biosimilars will impact the cost of cancer treatment.
Transcript:
Do anticancer biosimilars have a role in bringing down the cost of oncology care?
The role of biosimilars and the cost of cancer care remains to be determined. There is little doubt that the introduction of generics in the small molecules made a tremendous difference in terms of reducing the cost of cancer care. It was counterbalanced by the introduction of predominantly new biologics.
So that was the last 10 years, and now we’re entering a phase where the equivalent of “generic” biologics is starting to make an impact on the market. What we saw in the small-molecule generic was discounts ultimately as high as 80% or 90% as the third or fourth generic drug came to market. It has been argued that we will never see that kind of a discount in the biosimilar market because the compounds are far too complicated to manufacture and the regulatory burden on manufacturers to meet FDA muster is substantially greater, and that’s undoubtedly true.
But let’s remember that if you look at the cost of care over the last 10 years—the rise in the cost of cancer care related to drugs—are actually due to 2 classes of agents, 1 being oral specialty pharmacy agents where the increase is by far the greatest, but the second are the biologics.
So, even a 10% or 15% discount for a biosimilar agent that is embraced by the clinical community could mean millions or even billions of dollars for a payer. So, the answer is yes.
Now the fascinating thing is this week*, Coherus announced they were going to come in at 33% lower than the reference product, which is Neulasta. That has rocked the market a little bit and may wind up being a bellwether for what we’re going to see as we see other biosimilars, including the big therapeutic biosimilars which we’re going to see coming in the next couple of years—biosimilars for Herceptin and Rituxan—we will see.
The answer is it can’t not reduce the cost of care. It will reduce the cost of care. The question is how much.
*as of the date of filming.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.